Clinical Trial Update: Brentuximab Vedotin for Steroid Refractory GvHD [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating brentuximab vedotin for steroid-refractory graft-versus-host disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Graft vs. Host Disease | Phase 1 | Status: COMPLETED